About me
Miriam Jacobs, MD, is board-certified and fellowship-trained in medical oncology at MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital. As a specialist in early and advanced breast cancers, Dr. Jacobs provides chemotherapy, hormone therapy, immunotherapy, precision medicine, and clinical trials. She is also a member of the American Association of Cancer Research, the American Society of Hematology, and the American Society of Clinical Oncology.
Dr. Jacobs’ approach to care focuses on providing individualized and holistic treatments. She begins by talking with patients to learn about their medical histories and health goals. She then collaborates with an experienced team of radiation oncologists and surgeons to develop comprehensive and tailored wellness plans. She also educates patients about natural, traditional, and state-of-the-art cancer treatments.
Dr. Jacobs is dedicated to advancing the field of precision medicine – an innovative form of care that uses people’s own cells to develop highly personalized prevention, diagnosis, and treatment options. She is particularly interested in providing hormone receptor-positive, CAR T-cell, and CAR NK-cell therapies to improve the health of breast cancer survivors. Referring physicians should know that she is available to give second opinions and discuss clinical trial opportunities.
Philosophy of care
“Research creates endless possibilities to discover new methods of treating complex diseases or enhancing people’s lives. As a clinical researcher, I’m passionate about contributing to the collection of knowledge that can lead to immediate medical solutions or future health innovations. I’m also grateful to clinical trial participants who are true healthcare pioneers and heroes.”
About the MedStar Georgetown Cancer Institute
MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, the Georgetown Lombardi Comprehensive Cancer Center, is the only National Cancer Institute-designated comprehensive cancer center in the Washington, D.C., region. This partnership means we provide access to cutting-edge clinical trials and the latest breakthroughs in cancer care.
Clinical areas of focus
- Breast Cancer
- HER2 Positive Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
Conditions and procedures
Conditions I treat
- Abnormal Mammogram
- Adolescent And Young Adult Cancer (AYA)
- Atm Mutation
- Atypical Ductal Hyperplasia
- Atypical Lobular Hyperplasia
- Axillary Lymphadenopathy
- Breast Cancer
- HER2 Positive Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
Procedures I perform
- Adjuvant Chemotherapy
- Adjuvant Chemotherapy
- Adjuvant Radiation Therapy
- Areola Sparing Mastectomy
- Aromatase Inhibitor
Insurance
MedStar Health accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Health, please call your insurance company.
-
List of insurance plans we accept
- United Healthcare Choice Plus
- United Healthcare Choice
- UHC Community Plan of MD
- Optimum Choice Preferred (POS) & OCI Direct (HMO)
- Mamsi Life & Health (Indem./PPO)
- M.D. IPA Preferred (POS)
- M.D. IPA (HMO)
- Tricare Prime
- Tricare for Life (Medicare Supplemental Plan)
- Private Health Care Systems (PHCS) (PPO)
- MedStar Select (MedStar Associates' Plan)
- MedStar Family Choice - Maryland Health Choice
- Medicare Fee for Service
- Kaiser Virginia Premier
- Kaiser PermanenteSelect-Added Choice
- Kaiser Permanente Signature-Added Choice
- Kaiser Permanente Signature
- Kaiser Permanente Select
- Kaiser Permanente Medicare Plus (Medicare Supplemental Plan)
- Kaiser Permanente Medicare Advantage Signature and Select (aka Senior Advantage)
- Kaiser Permanente Flexible Choice POS
- Kaiser MD Medicaid MCO
- FIRST HEALTH
- First Health PPO
- Coventry of Delaware HMO/PPO
- Coventry Health Care of Virginia
- Coventry Health Care National Network PPO
- Great-West Healthcare POS/CIGNA
- CIGNA POS/Network POS
- CIGNA Indemnity
- POS OA & OA Plus
- Network OA
- CIGNA HMO Open Access (OA)
- CIGNA HMO & Network (HMO)
- Choice Fund PPO
- PPO and PPO Plus
- Cigna EPO
- HealthyBlue PPO
- CFBSBC Blue Preferred PPO
- CFBCBS Maryland Indemnity or PPO
- CFBCBS Maryland Point of Service Plan (MPOS)
- CFBCBS Federal Employee Program (Std/Basic PPO/Blue Focus)
- CFBCBS EPO
- CFBCBS BlueChoice HMO
- CFBCBS Blue Choice Opt Out Plus Open Access (POS)
- Blue Choice Advantage & Healthy Blue (HMO, POS)
- BlueChoice Open Access
- CFBCBS Blue Choice Opt Out Open Access
- CFBCBS (NCA) Indemnity
- Aetna Worker's Compensation Network
- Innovation Health: Indemnity
- Aetna Traditional Choice (PPO)
- Aetna Student Health Insurance
- Aetna Quality Point of Service (POS)
- Innovation Health: PPO
- Aetna Open Choice (PPO)
- Aetna Medicare Advantage HMO & PPO Plans
- Open POS II
- Innovation Health: Open POS Plus
- Choice POS & Choice POS II
- Aetna Managed Choice Open Access (POS)
- Innovation Health: POS Plus
- Aetna Managed Choice (POS)
- Open EPO Plus
- Opoen HMO Option
- Open HMO
- Innovation Health: POS
- Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
- Aetna Innovations: HMO & EPO Plus
- Select HMO/HealthFund/Health Network
- Aetna HMO
- Innovation Health: Open Network Only Plus
- Aetna Elect Choice/ Open Access (POS)
- Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
- UnitedHealthcare Medicare Adv/Special Needs Plans
- UnitedHealthcare and AARP Medicare Complete Plans/ UHC Group Medicare Advantage Plans HMO, POS, PPO
- United Student Resources
- United Healthcare Select Plus (POS)
- United Healthcare Select HMO - EPO/NPP
- United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)
Education
Board Certification: American Board of Internal Medicine, Internal Medicine
Board Certification: American Board of Internal Medicine, Medical Oncology
Fellowship Program: Washington University/Barnes Jewish Hospital (2021)
Residency Program: University of California San Diego (2015)
Medical School: Ben Gurion University (2012)
Awards
- Abstract Achievement Award, American Society of Hematology (December 2019) Dean’s Scholar Award, Washington University School of Medicine (July 2022-Present)
Hospital affiliations
News and publications
A Noncompetitive Inhibitor of Serotonin Transport, Acts by Stabilizing the Cytoplasmic-Facing Form of the Transporter, Journal of Biological Chemistry, August 2007
A Conformational Mechanism for Neurotransmitter Transporters, Proceedings of the National Academy of Sciences, July 2008
A Conserved Asparagine Residue in TM1 of the Serotonin Transporter Dictates Chloride-Coupled Neurotransmitter Transport, Journal of Biological Chemistry, July 2011
Use of Low Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small Cell Lung Cancer, JCO Precision Oncology, 2018
Genomic Landscape of Appendiceal Neoplasms, JCO Precision Oncology, 2018
The Use of Ruxolitinib for Acute Graft-Versus Host Disease Developing After Solid Organ Transplantation, American Journal of Transplantation, February 2020
Outcomes of Patients with Large B-Cell Lymphoma Progressing After Axicabtagene Cilolecuel Therapy, Blood, April 1, 2021
Memory-Like Differentiation Enhances NK Cell Response to Melanoma, Clinical Cancer Research, August 3, 2021
CD7 Deleted Hematopoietic Stem Cells Can Restore Immunity After CAR T-Cell Therapy, Journal of Clinical Investigation Insights, August 23, 2021
Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated with Natural Killer Cell Adoptive Therapy, Blood, February 24, 2022
Hematopoietic Cell Transplantation Donor-Derived Memory-Like NK Cells Functionally Persist After Transfer Into Patients with Leukemia, Science Translational Medicine, February 23, 2022
Severity of Cytokine Release Syndrome Influences Outcomes After Axicabtagene Ciloleucel for Large B Cell Lymphoma, Clinical Lymphoma Myeloma and Leukemia, October 22, 2022
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice, Journal of Clinical Oncology, December 2022